Envafolimab (KN035)
Various cancers (PD-L1 inhibitor)
Phase 3Active
Key Facts
About AlphaMab Oncology
AlphaMab Oncology develops innovative bispecific antibodies and ADCs for cancer treatment using proprietary glycan-specific conjugation and CRIB platforms.
View full company profile